Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0524 (Niacin + Laropiprant) Dose Ranging Study for Flushing
NCT00111891Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2005
- Primary completion
- Aug 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of laropiprant in dyslipidemia (2 arms), sponsored by Merck & Co. Primary endpoint: Acute cutaneous symptoms induced by niacin at 7 days. Started Jun 2005; status: completed.
02
Drugs
laropiprant
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT00111891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111891.